LYEL

Lyell Immunopharma Inc

11.04

Oct 30 • 3:59 PM ET -0.27 (-2.34%)

11.04

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: ALLO AUTL CRBU ACET FATE NKTX LEGN SANA CABA GILD

| Held by: VTI IWM VXF IWN IBB SCHA VTWO IWC VHT BUSM

Scroll to Statements

Index	RUT
Market Cap	270.54M
Enterprise Value	113.04M
Income	-248.48M
Sales	0.03M
Book/sh	9.99
Cash/sh	8.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	161
IPO	Jun 17, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	9018.00
P/B	1.10
P/C	1.33
P/FCF	-
EV/EBITDA	-
EV/Sales	3768.00
Quick Ratio	5.36
Current Ratio	5.36
Debt/Eq	0.20
LT Debt/Eq	0.16
Option/Short	Yes / Yes

EPS (ttm)	-11.77
EPS next Y	-7.59
EPS next Q	-2.03
EPS this Y	54.95%
EPS next Y	-4.98%
EPS next 5Y	26.95%
EPS past 3/5Y	-2.70% 0.99%
Sales past 3/5Y	-92.48% -65.85%
EPS Y/Y TTM	51.58%
Sales Y/Y TTM	-55.00%
EPS Q/Q	33.61%
Sales Q/Q	-50.00%
Earnings	Aug 12 AMC
EPS/Sales Surpr.	-1.05% 11.11%

Insider Own	63.83%
Insider Trans	-0.11%
Inst Own	21.31%
Inst Trans	-0.40%
ROA	-71.34%
ROE	-93.28%
ROIC	-91.77%
Gross Margin	-35148.15%
Oper. Margin	-729281.48%
Profit Margin	-920285.19%
SMA20	20.52%
SMA50	0.15%
SMA200	-34.55%
Trades

Shs Outstand	23.40M
Shs Float	8.86M
Short Float	15.78%
Short Ratio	9.20
Short Interest	1.40M
52W High	45.00 -75.47%
52W Low	7.20 53.44%
Volatility	7.38% 8.17%
ATR (14)	0.72
RSI (14)	61.43
Beta	-0.02
Rel Volume	0.74
Avg Volume	152.00K
Volume	113,165

Perf Week	17.57%
Perf Month	17.32%
Perf Quarter	-14.22%
Perf Half Y	-47.00%
Perf YTD	-64.13%
Perf Year	-33.21%
Perf 3Y	-69.16%
Perf 5Y	-96.04%
Perf 10Y	-
Recom	1.57
Target Price	37.71
Prev Close	11.31
Price	11.04
Change %	-2.34%

Consensus

Buy

Avg. Price Target

$37.71

Implied Upside

+241.6%

Analysts10incl. previous ratings

Rating Distribution6 Buy · 3 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 06, 2026	Initiated	SStifel	Buy	$36	+226.1%
Jul 22, 2026	Initiated	RB. Riley Securities	Buy	$44	+298.6%
May 01, 2026	Initiated	RRobert W. Baird	Outperform	$49	+343.8%
Apr 10, 2026	Initiated	NNeedham	Buy	$44	+298.6%
Mar 09, 2026	Initiated	CCitizens	Mkt Outperform	$34	+208.0%
Dec 09, 2025	Upgrade	HH.C. Wainwright	Neutral → Buy	$45	+307.6%
Oct 30, 2024	Downgrade	BBofA Securities	Buy → Underperform	$6 → $1	-90.9%
Jun 27, 2024	Downgrade	HH.C. Wainwright	Buy → Neutral	$6 → $1	-90.9%
Aug 28, 2023	Downgrade	JJP Morgan	Overweight → Neutral	$15 → $5	-54.7%
Nov 14, 2022	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$15 → $7	-36.6%
Nov 11, 2022	Downgrade	GGoldman	Buy → Neutral	$13 → $7	-36.6%
Oct 17, 2022	Initiated	HH.C. Wainwright	Buy	$12	+8.7%
Jul 12, 2021	Initiated	MMorgan Stanley	Overweight	$25	+126.4%
Jul 12, 2021	Initiated	JJP Morgan	Overweight	$22	+99.3%
Jul 12, 2021	Initiated	GGoldman	Buy	$30	+171.7%
Jul 12, 2021	Initiated	BBofA Securities	Buy	$25	+126.4%

Sep-14-26 07:00AM	Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference (GlobeNewswire) -5.27%
Sep-10-26 04:05PM	Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer (GlobeNewswire) -5.28%
Aug-06-26 05:39PM	Lyell Immunopharma: Q2 Earnings Snapshot (Associated Press) +5.65%
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 (GlobeNewswire)
09:48AM	Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Loading…
Jun-25-26 08:00AM	Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference (GlobeNewswire)
Jun-12-26 12:45PM	Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress (GlobeNewswire)
Jun-08-26 06:00AM	Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion (GlobeNewswire)
Jun-04-26 04:05PM	Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress (GlobeNewswire) -8.28%
Jun-01-26 08:00AM	Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026 (GlobeNewswire)
May-20-26 04:48PM	Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL) (Quartz) +6.76%
May-12-26 08:00AM	Lyell Immunopharma Announces Participation in May Investor Conferences (GlobeNewswire)
May-06-26 05:17PM	Lyell Immunopharma: Q1 Earnings Snapshot (Associated Press)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 (GlobeNewswire)
Apr-07-26 08:00AM	Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
06:10PM	Loading…
Mar-12-26 06:10PM	Lyell Immunopharma: Q4 Earnings Snapshot (Associated Press Finance) -14.23%
04:05PM	Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results (GlobeNewswire)
Mar-09-26 08:00AM	Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer (GlobeNewswire) +13.54%
Feb-23-26 08:00AM	Lyell Immunopharma Announces Participation in March Investor Conferences (GlobeNewswire) +6.12%
Feb-13-26 06:00AM	Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs (BioPharma Dive)
Feb-12-26 07:30AM	Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma (GlobeNewswire)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks) -9.09%
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-19-25 07:44AM	Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 (PR Newswire)
Dec-07-25 04:30PM	Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition (GlobeNewswire)
Nov-12-25 05:40PM	Lyell Immunopharma: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 (GlobeNewswire)
05:20AM	Metagenomi, Ovid CEOs step aside; Cogent soars on unprecedented stomach cancer data (BioPharma Dive)
Nov-11-25 08:44AM	Lyell acquires worldwide rights from ICT to CAR T-cell therapy (Pharmaceutical Technology)
Nov-10-25 07:30AM	Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer (GlobeNewswire)
09:00AM	Loading…
Nov-03-25 09:00AM	Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition (GlobeNewswire)
Sep-03-25 08:00AM	Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee (GlobeNewswire)
Sep-02-25 04:05PM	Lyell Immunopharma Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-12-25 06:17PM	Lyell Immunopharma: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 (GlobeNewswire)
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire) -6.26%
Jul-25-25 08:00AM	Lyell Immunopharma Announces up to $100 Million Equity Private Placement (GlobeNewswire) +19.31%
Jun-23-25 05:00PM	Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series (GlobeNewswire) +6.62%
Jun-18-25 07:12AM	Lyell reports new clinical data from trial of large B-cell lymphoma therapy (Clinical Trials Arena)
Jun-17-25 06:30AM	Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma (GlobeNewswire)
Jun-09-25 04:05PM	Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments (GlobeNewswire) -13.39%
Jun-04-25 04:05PM	Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) +68.59% -14.92%
May-13-25 05:49PM	Lyell Immunopharma: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 (GlobeNewswire)
May-01-25 09:00AM	Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025 (GlobeNewswire)
Apr-15-25 09:00AM	Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma (GlobeNewswire)
Mar-28-25 10:54AM	Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March? (Insider Monkey) -8.83%
Mar-11-25 04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024 (GlobeNewswire)
Feb-18-25 04:05PM	Lyell Immunopharma Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-22-25 12:00PM	Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why (Zacks)
Jan-09-25 09:00AM	Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference (GlobeNewswire)
Dec-31-24 09:35AM	After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) (Zacks)
Dec-30-24 09:35AM	After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) (Zacks)
Dec-13-24 09:35AM	Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround (Zacks) -11.37%
Dec-09-24 09:00PM	Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting (GlobeNewswire)
Nov-14-24 12:00PM	Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-07-24 05:22PM	Lyell Immunopharma: Q3 Earnings Snapshot (Associated Press Finance) -17.57%
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 (GlobeNewswire)
Nov-05-24 09:30AM	Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-24 04:00PM	Lyell Immunopharma Completes Acquisition of ImmPACT Bio (GlobeNewswire) +11.88% +16.63%
Oct-30-24 11:16AM	Lyell shares down as BofA double downgrades to Sell (Investing.com) -9.47%
Oct-25-24 11:56AM	Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline (Pharmaceutical Technology) -14.95%
Oct-24-24 04:00PM	Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies (GlobeNewswire) -5.22%
01:54PM	Lyell, in search of a turnaround, to buy cell therapy startup ImmPact (BioPharma Dive)
Oct-04-24 09:00AM	Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-24-24 04:05PM	Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day (GlobeNewswire) -7.53%
Aug-28-24 04:05PM	Lyell Immunopharma Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-07-24 05:41PM	Lyell Immunopharma: Q2 Earnings Snapshot (Associated Press Finance) +6.38%
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 (GlobeNewswire)
Aug-06-24 08:00AM	3 Biotech Stocks to Sell in August Before They Crash & Burn (InvestorPlace)
Jun-26-24 02:44PM	Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial (Benzinga) -36.03%
07:00AM	Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology (GlobeNewswire)
Jun-03-24 04:05PM	Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) -5.68%
May-07-24 04:05PM	Lyell Immunopharma to Participate in BofA Securities Health Care Conference (GlobeNewswire)
May-06-24 10:53PM	LYEL Stock Earnings: Lyell Immunopharma Beats EPS for Q1 2024 (InvestorPlace) +7.63%
01:34PM	Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows (MT Newswires)
08:23AM	Lyell Immunopharma: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 (GlobeNewswire)
Mar-19-24 10:00AM	CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) (GlobeNewswire)
Mar-07-24 12:00PM	Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know (Zacks)
Mar-05-24 04:30PM	Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting (GlobeNewswire) +5.18%
Feb-28-24 04:44PM	Lyell Immunopharma Inc (LYEL) Reports 2023 Financial Results and Business Highlights (GuruFocus.com)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
Feb-26-24 04:05PM	Lyell Immunopharma Announces Participation in March Investor Conferences (GlobeNewswire) +9.62% +8.78%
Jan-03-24 04:05PM	Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.69%
Nov-09-23 04:05PM	Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma (GlobeNewswire) -6.81% -24.43%
Nov-07-23 04:33PM	Lyell Immunopharma: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023 (GlobeNewswire)
Oct-31-23 09:00AM	Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing (GlobeNewswire) -7.54%
Sep-27-23 09:00AM	Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-11-23 08:00AM	Cellares and Lyell to Evaluate Automated Manufacturing of Lyells CAR T-Cell Therapy on Cellares Cell Shuttle Platform (GlobeNewswire) +9.89%
Aug-31-23 04:05PM	Lyell Immunopharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-23 07:10PM	Lyell Immunopharma: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023 (GlobeNewswire)
Jul-12-23 08:47AM	Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jul-05-23 04:05PM	Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer (GlobeNewswire) -6.98%
Jun-16-23 10:47AM	Why Shares of Lyell Immunopharma Jumped This Week (Motley Fool) -17.36%
Jun-07-23 04:05PM	Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference (GlobeNewswire) -5.52%
Jun-01-23 07:55AM	Even after rising 12% this past week, Lyell Immunopharma (NASDAQ:LYEL) shareholders are still down 31% over the past year (Simply Wall St.)
May-04-23 07:25PM	Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aguirre Jarrad Mattieu	Chief Medical Officer	Oct 12 '26	Sale	8.63	422	3,642	19,857	Oct 13 05:17 PM
Shook David	Chief Medical Officer	Sep 10 '26	Sale	12.70	500	6,350	20,423	Sep 10 07:37 PM
Seely Lynn	President and CEO	Aug 21 '26	Sale	15.54	9,589	149,013	63,899	Aug 25 04:06 PM
Hill Stephen J.	Chief Operating Officer	Aug 21 '26	Sale	15.54	989	15,369	16,816	Aug 25 04:05 PM
Lee Gary K.	Chief Scientific Officer	Aug 21 '26	Sale	15.54	1,457	22,642	16,220	Aug 25 04:03 PM
Bulis Veronica Sanchez	VP, Corporate Controller	Aug 10 '26	Sale	14.34	621	8,905	14,799	Aug 11 04:21 PM
Lee Gary K.	Chief Scientific Officer	Aug 10 '26	Sale	14.34	131	1,879	17,677	Aug 11 04:20 PM
Hill Stephen J.	Chief Operating Officer	Aug 10 '26	Sale	14.34	89	1,276	17,805	Aug 11 04:18 PM
Seely Lynn	President and CEO	Aug 10 '26	Sale	14.34	390	5,593	73,488	Aug 11 04:07 PM
Innovative Cellular Therapeuti	10% Owner	Jul 17 '26	Sale	13.70	10	137	2,857,480	Jul 20 02:55 PM
Innovative Cellular Therapeuti	10% Owner	Jul 16 '26	Sale	13.73	10	137	2,857,490	Jul 17 09:45 PM
Seely Lynn	President and CEO	May 11 '26	Sale	18.91	388	7,337	73,878	Jun 15 06:37 PM
Lee Gary K.	Chief Scientific Officer	May 11 '26	Sale	18.92	130	2,460	17,808	Jun 15 06:35 PM
Hill Stephen J.	Chief Operating Officer	May 11 '26	Sale	18.92	89	1,684	17,894	Jun 15 06:34 PM
Bulis Veronica Sanchez	VP, Corporate Controller	May 11 '26	Sale	18.91	217	4,103	15,420	Jun 15 06:32 PM
Shook David	Chief Medical Officer	Jun 10 '26	Sale	12.64	1,977	24,989	20,923	Jun 11 04:07 PM
ARCH Venture Partners IX, LLC	10% Owner	Mar 06 '26	Buy	25.61	488,090	12,499,985	1,426,528	Mar 09 04:36 PM
ARCH Venture Fund XIII, L.P.	10% Owner	Mar 06 '26	Buy	25.61	488,090	12,499,985	1,426,528	Mar 09 04:34 PM
Seely Lynn	President and CEO	Feb 11 '26	Sale	23.39	7,455	174,372	74,266	Feb 12 08:47 PM
Hill Stephen J.	Chief Operating Officer	Feb 11 '26	Sale	23.39	1,236	28,910	17,795	Feb 12 08:46 PM
Lee Gary K.	Chief Scientific Officer	Feb 11 '26	Sale	23.39	1,671	39,085	16,938	Feb 12 08:44 PM
Hill Stephen J.	Chief Operating Officer	Feb 10 '26	Sale	23.12	109	2,520	19,031	Feb 11 09:05 PM
Lee Gary K.	Chief Scientific Officer	Feb 10 '26	Sale	23.12	147	3,399	18,609	Feb 11 09:04 PM
Seely Lynn	President and CEO	Feb 10 '26	Sale	23.12	438	10,127	81,721	Feb 11 09:03 PM
Bulis Veronica Sanchez	VP, Corporate Controller	Feb 10 '26	Sale	23.12	254	5,872	15,637	Feb 11 09:00 PM
Bulis Veronica Sanchez	VP, Corporate Controller	Dec 24 '25	Sale	38.67	1,136	43,929	8,077	Jan 06 04:02 PM
Bulis Veronica Sanchez	VP, Corporate Controller	Dec 30 '25	Sale	32.32	936	30,252	7,141	Jan 06 04:02 PM
Seely Lynn	President and CEO	Nov 10 '25	Sale	16.11	412	6,637	67,159	Nov 12 08:36 PM
Bulis Veronica Sanchez	VP, Corporate Controller	Nov 10 '25	Sale	16.10	239	3,848	9,213	Nov 12 08:34 PM
Lee Gary K.	Chief Scientific Officer	Nov 10 '25	Sale	16.16	138	2,230	15,366	Nov 12 08:33 PM
Hill Stephen J.	Chief Operating Officer	Nov 10 '25	Sale	16.12	95	1,531	15,750	Nov 12 08:31 PM

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Founder & Executive ChairmanDr. Richard D. Klausner M.D.

Ph.D.Dr. Lynn Seely M.D.

Chief Operating OfficerMr. Stephen J. Hill M.B.A.

Chief Scientific OfficerDr. Gary K. Lee Ph.D.

Founder & Scientific AdvisorProf. Stanley R. Riddell M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LYEL

Lyell Immunopharma Inc

Upgrade your Finviz experience